Reports Q1 revenue $203M, consensus $202.2M. “Since stepping into this role, I have dedicated my time strengthening our leadership team, gaining a deeper understanding of our business, meeting with key partners, understanding the macroeconomic environment, and identifying key capabilities and growth opportunities,” said Wendy Barnes, Chief Executive Officer and President of GoodRx (GDRX). “I can confidently say that we are in a very strong position to deliver meaningful value across the pharmacy ecosystem. Furthermore, we are focused on high-impact initiatives that we believe will drive our business forward in compelling ways.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- Notable companies reporting before tomorrow’s open
- GoodRx price target lowered to $7 from $8 at Wells Fargo
- GoodRx Holdings: Strategic Positioning and Cost Advantages Support Buy Rating Amidst Competitive Landscape
- GoodRx price target lowered to $5.50 from $6.50 at Truist
- Cautious Outlook for GoodRx Holdings Amid Limited Partnership Impact and Industry Challenges